Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress®) injections: a two-centre study: reply to comment by Hurtado and Appell

Annette Kuhn

Received: 6 June 2008 / Accepted: 12 June 2008 / Published online: 18 July 2008
© The International Urogynecological Association 2008

Dear Editor,

I thank Dr. Hurtado and Dr. Appell for their comment [1] on the long-term results after transurethral injection of ethylene vinyl alcohol [2].

We criticized the additional amount of injectable in the study carried out by Hurtado and colleagues on the basis of the data of the original European multicentre study; these data have unfortunately never been published but showed a dose-dependent increase of complications. This study was performed in the late 1990s, and at that time the appropriate amount of ethylene vinyl alcohol was unclear as only animal data were available. The latter confirmed material consistence and lack of migration. An interim analysis of data showed a correlation of postoperative complications and amount of injected material, which resulted in the specific dose recommendations that were advised for the used amount of ethylene vinyl alcohol by the manufacturer. This is the background to our discussion of this point quoting the study by Hurtado et al. [3].

I absolutely agree with Hurtado and Appell that the difference in the proportion of naïve patients in their study compared to ours can result in different outcomes; I am sure that any kind of urethral scarring as in the quoted study including male patients after prostatectomy [4] or previous injections with permanent materials will make further injectable treatment difficult and possibly increase the risk for urethral erosion.

I do not consider our success rate of 42% as exceptionally good for a surgical incontinence procedure; possibly it was just by chance that we did not see urethral erosions in our study of only 33 patients, which is indeed not a large number.

I am not well informed of the reasons for withdrawal of the substance but assume that *any* report of urethral erosion after transurethral injection must be considered a serious adverse event. I guess that complications, particularly after so-called minimally invasive procedures, are often under-reported.

We must be cautious using permanent injectables for which there are no long-term data. This is the reason why we implant new substances or devices for incontinence under study conditions and after detailed patient information only.

References

1. Hurtado EA, Appell RA (2008) Complications of Tegress® injections. Int Urogynecol J doi:10.1007/s00192-008-0674-z
2. Kuhn A, Stadlmayr W, Sohail A, Monga A (2008) Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress®) injections: a two-centre study. Int Urogynecol J 19:503–507 doi:10.1007/s00192-007-479-5
3. Hurtado E, McCrery R, Appell R (2007) The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic sphincter deficiency. Int Urogynecol J 18:869–873 doi:10.1007/s00192-006-0251-2
4. Hurtado E, McCrery R, Appell R (2008) Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinence. Urology 71:662–665

A. Kuhn (✉)
Frauenklinik, Inselspital,
3010 Bern, Switzerland
e-mail: annette.kuhn@insel.ch